Profound tumor-specific Th2 bias in patients with malignant glioma

BMC Cancer

Table 3 Frequencies of response among subjects to the candidate glioma-associated T helper cell epitopes

	MAGE-A3_112-127	MAGE-A3_121-136	MAGE-A3_143-160	IL-13Rα2_341-355	IL-13Rα2_351-365
Primary GBM 1		++	++++	+	+++
Primary GBM 2	++	++	+++	++	++
Primary GBM 3	++	++++	+	+++++	++
Primary GBM 4	+	++	+		+++
Primary GBM 5	+++++	++++	+	++	+
Primary GBM 6	++	++	+	++
Primary GBM 7	+++	++++	++	+++	+++
Primary GBM 8	++++	++	+++++	++++	+++++
Recurrent GBM 1	+	++	+	++	++
Recurrent GBM 2	+
Recurrent GBM 3	++	+	+		+
Recurrent GBM 4	++	+	+
Recurrent GBM 5	+	+			++
Meningioma 1		+
Meningioma 2		+++
Meningioma 3					+
Meningioma 4			+
Meningioma 5	+++			++	++
Meningioma 6	+	+	+	+	++++++
Meningioma 7			+
Healthy Subject 1	+++	+++	+++		+
Healthy Subject 2		+	+++	+
Healthy Subject 3	++	+++	+
Healthy Subject 4	++	+	+++++	+	+++++
Healthy Subject 5	+	+	++	++++	++
Healthy Subject 6		+	+	+	++

Cytokine production was quantified by ELISA, defining a positive T cell response for each patient as the amounts of IFN-γ or IL-5 that were > 50 pg/mL and two standard deviations above the mean cytokine levels secreted after stimulation of cells from that patient with negative control MBP peptide. A total of 6 primary T cell responses were measured for each subject against each peptide. (+) symbols indicate the precise number of positive wells among six for each peptide.

ISSN: 1471-2407